The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Completed

• Conditions: Eisenmenger's Syndrome

• Registration Number: NCT01283958
• Lead Sponsor: Gachon University Gil Medical Center

Brief Summary

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-09
• Status Verified: 2010-05
• Study Completion: 2010-05
• Study First Submitted: 2011-01-25
• Study First Submitted QC: 2011-01-25
• Last Update Submitted: 2011-01-25
• Study First Posted: 2011-01-26
• Last Update Posted: 2011-01-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified